zinc finger protein 250Genealiases: ZFP647 · ZNF647
Q-omics provides the consensus-scored ZNF250 profile across patient tissues and cancer cell-line models. ZNF250 expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, ZNF250 is differentially expressed in 9, with the highest sampling consensus in HNSC. Additionally, ZNF250 RNA expression shows 21,565 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight ACC, and HNSC as cancer lineages where ZNF250 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ZNF250 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ZNF250 survival associations across molecular data types. ZNF250 RNA expression shows survival associations in the most cancer types (27), followed by mutation status (4) and mass-spec protein abundance (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ZNF250 RNA expression–survival associations across cancer types. High ZNF250 expression shows unfavorable associations in ACC, LIHC, UVM and LUSC, but favorable associations in KIRC and HNSC. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for ZNF250 RNA expression.
This table summarizes ZNF250 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9, while mass-spec protein shows differences in 2. The strongest signals are observed in HNSC for RNA and OV for protein.
This table ranks reproducible tumor–normal expression differences for ZNF250. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ZNF250 shows lower tumor expression in THCA and higher tumor expression in HNSC, COAD, LIHC, KIRP and BRCA. The HNSC box plot shows higher ZNF250 RNA expression in tumor versus normal tissue (log2 FC = +0.593, t-test p < 0.001).
This table shows molecular features associated with ZNF250 in patient tissues and cancer cell lines. In patient samples, ZNF250 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, ZNF250 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OESOPHAGUS, while CRISPR and shRNA rows add functional-dependency signals in SOFT_TISSUE and BLOOD_Leukemia.
